


**CONTINUED PROSECUTION APPLICATION (CPA)
REQUEST TRANSMITTAL**

 Submit an original, and a duplicate for fee processing.
 (Only for Continuation or Divisional applications under 37 CFR 1.53(d))
RECEIVED

MAR 24 2000

Address to:	Attorney Docket No.	TECH CENTER 1600/2600 DM-6864-A
Assistant Commissioner for Patents Box CPA Washington, DC 20231	First Named Inventor	He et al.
	Express Mail Label No.	EL502307999US
	Express Mailing Date	March 21, 2000

This is a request for a continuation or divisional application under 37 CFR 1.53(d), (continued prosecution application (CPA)) of prior application number 09/015,002, filed on January 28, 1998, entitled Azolotriazines and Pyrimidines.

NOTES

FILING QUALIFICATIONS: The prior application identified above must be a non-provisional application that is either: (1) complete as defined by 37 CFR 1.51(b), or (2) the national stage of an international application in compliance with 35 U.S.C. 371.

C-I-P NOT PERMITTED: A continuation-in-part application cannot be filed as A CPA under 37 CFR 1.53(d), but must be filed under 37 CFR 1.53(b).

EXPRESS ABANDONMENT OR PRIOR APPLICATION: The filing of this CPA is a request to expressly abandon the prior application as of the filing date of the request for a CPA. 37 CFR 1.53(b) must be used to file a continuation, divisional, or continuation-in-part of an application that is not to be abandoned.

ACCESS TO PRIOR APPLICATION: The filing of this CPA will be construed to include a waiver of confidentiality by the applicant under 35 U.S.C. 122 to the extent that any member of the public who is entitled under the provisions of 37 CFR 1.14 to access to, copies of, or information concerning, the prior application may be given similar access to, copies of, or similar information concerning, the other application in the file jacket.

35 U.S.C. 120 STATEMENT: In a CPA, no reference to the prior application is needed in the first sentence of the specification and none should be submitted. If a sentence referencing the prior application is submitted, it will not be entered. A request for a CPA is the specific reference required by 35 U.S.C. 120 and to every application assigned the application number identified in such request, 37 CFR 1.78(a).

1. Enter the unentered amendment previously filed on _____ under 37 CFR 1.116 in the prior non-provisional application.
2. A preliminary amendment is enclosed.
3. This application is filed by fewer than all the inventors named in the prior application, 37 CFR 1.53(d)(4). DELETE the following inventor(s) named in the prior non-provisional application:
4. A new power of attorney or authorization of agent is enclosed.
5. Information Disclosure Statement (IDS) is enclosed:
 - a. Cover Letter and PTO-1449
 - b. Copies of IDS Citations
6. Return Receipt Postcard (MPEP 503)

Please type a plus sign (+) inside this box →

PTO/SB/29

As modified by DuPont Pharmaceuticals Company
Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

CLAIMS	(1) FOR	(2) NUMBER FIELD	(3) NUMBER EXTRA	(4) RATE	(5) CALCULATIONS RECEIVED
	TOTAL CLAIMS (37 CFR 1.16(C))	- () =		x \$ () =	
	INDEPENDENT CLAIMS (37 CFR 1.16(b))	- () =		x \$ () =	MAR 24 2000
	MULTIPLE DEPENDENT CLAIM(S) (if applicable)			= \$270 =	TECH CENTER 1600/2000
				BASIC FEE (37 CFR 1.16(a))	\$690.00
				TOTAL =	\$690.00

7. The Commissioner is hereby authorized to credit overpayments or charge the following fees to Deposit Account No. 04-1928:

a. Fees required under 37 CFR 1.16.
b. Fees required under 37 CFR 1.17
8. Other:

Priority of foreign application no. _____	filed on _____	in _____	is _____
9. <input type="checkbox"/> _____	(country)		
claimed under 35 U.S.C. 119.			

10. Other papers enclosed: _____

11. CORRESPONDENCE ADDRESS

NAME	Kenneth B. Rubin			
ADDRESS	1007 Market Street			
CITY	Wilmington	STATE	Delaware	ZIP CODE
COUNTRY	U.S.A.	TELEPHONE	302-992-3215	FAX
	19898			
	302-992-6659			

12. SIGNATURE OF ATTORNEY OR AGENT REQUIRED

NAME	Kenneth B. Rubin		REG. NO.: 36,259
SIGNATURE			
DATE	March 21, 2000		